On March 29, 2007 an FDA panel voted 17-0 on safety and 13-4 in efficacy for late stage prostate cancer patients. Since then, Dendreon has flown high and is about to crash with the hopes of their patients, advocates, and investors.
In the meantime, the FDA is on a half baked mission to change itself. It is stuck in the Stone Age. There way of carrying out their mission would offend the Geico cave men.